Home › Companies › Astria Therapeutics, Inc. › 2025-2026

Astria Therapeutics, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Astria Therapeutics, Inc.’s Form 8-K, filed 2026-01-21 (Item 5.07 on EDGAR). Page generated 04 October 2026.

4Reported items
155Asset managers
548Fund votes
2026-01-21Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Astria Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Astria Therapeutics, Inc.

These tallies are Astria Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-01-21 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Astria Therapeutics, Inc. — official shareholder meeting results, meeting held 2026-01-21
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Compensation Proposal At the Special Meeting, the Company's stockholders also voted upon and approved, on a non-binding, advisory basis, the Merger-related named executive officer compensation as disclosed in the table entitled "Golden Para	33,236,762	2,035,104	485,206	--	--	Passed

Source: Astria Therapeutics, Inc., Form 8-K, filed with the SEC on 2026-01-21 — read the filing on EDGAR.

How asset managers voted at the Astria Therapeutics, Inc. 2025-2026 meeting

Each item below shows how the 155 asset managers that disclosed a Astria Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Astria Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To cast a vote, on a non-binding, advisory basis, to approve the Merger-related named executive officer compensation as disclosed in the table entitled "Golden Parachute Compensation" and its accompanying footnotes which is included in the section of the proxy statement entitled "The Merger- Interests of Astria's Directors and Executive Officers in the Merger," as required by Section 14A of the Se

SECTION 14A SAY-ON-PAY VOTESCompany result: Passed

Combines 13 wordings of this item as funds reported it.

94% Passed · of votes cast

FOR 94%

FOR: 33,236,762AGAINST: 2,035,104

Astria Therapeutics, Inc.’s own tally for this item (“Compensation Proposal At the Special Meeting, the Company's stockholders also voted upon and approved, on a non-binding, advisory basis, the Merger-related named executive officer compensation as disclosed in the table e”): 33,236,762 for, 2,035,104 against — passed, per its Form 8-K filed 2026-01-21 (Item 5.07).

The 152 asset managers below cast 93% of the shares they voted on this item FOR (31,294,424 for, 2,189,917 against).

FOR 92%

FOR: 31,294,424 (92.3%)AGAINST: 2,189,917 (6.5%)ABSTAIN: 410,606 (1.2%)NOT VOTED: 123 (0.0%)

Largest asset managers voting on “To cast a vote, on a non-binding, advisory basis, to approve the Merger-related named executive officer compen” at Astria Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
PERCEPTIVE ADVISORS LLC	4,460,827	0	For
BlackRock	3,219,029	723	For
GLAZER CAPITAL, LLC	2,955,200	0	For
Vanguard	2,249,009	0	For
AllianceBernstein	0	1,718,108	Against
Magnetar Financial LLC	1,570,230	0	For
GEODE CAPITAL MANAGEMENT, LLC	1,008,484	0	For
ADAGE CAPITAL PARTNERS GP, L.L.C.	900,000	0	For
Gabelli	887,000	0	For
Fidelity	876,739	0	For
Nantahala Capital Management, LLC	869,530	0	For
Citadel	797,702	0	For
State Street	792,476	848	For
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND	741,684	0	For
Charles Schwab	687,513	0	For
Vivo Capital, LLC	681,199	0	For
ALPINE ASSOCIATES MANAGEMENT INC.	663,817	0	For
Investment Managers Series Trust II	662,738	0	For
WATER ISLAND CAPITAL LLC	604,390	0	For
AQR	593,968	0	For
GARDNER LEWIS ASSET MANAGEMENT L P	587,733	0	For
BALYASNY ASSET MANAGEMENT L.P.	559,908	0	For
Chicago Capital Management, LLC	530,000	0	For
MARSHALL WACE, LLP	401,391	0	For
ARBITRAGE FUNDS	389,533	0	For

Showing the 25 largest of 152 asset managers. See all 152 in the interactive database.

2. TO APPROVE ONE OR MORE ADJOURNMENTS OF THE SPECIAL MEETING TO A LATER DATE OR DATES IF THERE ARE NOT SUFFICIENT VOTES FOR ADOPTION OF THE MERGER PROPOSAL ON THE DATE ON WHICH THE SPECIAL MEETING IS HELD.

CORPORATE GOVERNANCE

99.4% fund support · no official result

FOR 99.3%

The 47 asset managers below cast 99.4% of the shares they voted on this item FOR (6,990,168 for, 40,211 against).

FOR: 6,990,168 (99.4%)AGAINST: 40,211 (0.6%)ABSTAIN: 4,530 (0.1%)

Largest asset managers voting on “TO APPROVE ONE OR MORE ADJOURNMENTS OF THE SPECIAL MEETING TO A LATER DATE OR DATES IF THERE ARE NOT SUFFICIEN” at Astria Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	1,951,873	0	0	For
BlackRock	1,702,758	0	0	For
Fidelity	870,835	0	0	For
Investment Managers Series Trust II	662,738	0	0	For
ARBITRAGE FUNDS	389,533	0	0	For
Charles Schwab	343,718	0	0	For
Dimensional	121,077	0	0	For
Morningstar Funds Trust	115,651	0	0	For
Equitable	102,597	0	0	For
TIAA	90,426	0	0	For
ALTSHARES TRUST	88,638	0	0	For
American Century	84,106	0	0	For
Tidal Trust II	75,288	0	0	For
Bridge Builder Trust	71,393	0	0	For
QUANTITATIVE MASTER SERIES LLC	65,938	0	0	For
New York Life	30,770	0	0	For
ALPS ETF Trust	26,220	0	0	For
ETFis Series Trust I	24,635	0	0	For
Lincoln Financial	0	21,100	0	Against
Northern Trust	20,702	0	0	For
Global X	17,869	0	0	For
AIG/SunAmerica	17,591	0	0	For
Brighthouse	11,895	0	4,530	For
State Street	0	13,152	0	Against
Pacific Life	13,126	0	0	For

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

3. To adopt the Agreement and Plan of Merger, dated as of October 14, 2025 by and among BioCryst Pharmaceuticals, Inc. ("BioCryst"), Axel Merger Sub, Inc., a wholly owned subsidiary of BioCryst ("Merger Sub"), and Astria Therapeutics, Inc. ("Astria"), under which Merger Sub will merge with and into Astria, with Astria surviving and becoming a wholly owned subsidiary of BioCryst (the "Merger") (the "M

EXTRAORDINARY TRANSACTIONS

Combines 2 wordings of this item as funds reported it.

100% fund support · no official result

FOR 100%

The 36 asset managers below cast 100% of the shares they voted on this item FOR (4,494,368 for, 0 against).

FOR: 4,494,368 (100.0%)

Largest asset managers voting on “To adopt the Agreement and Plan of Merger, dated as of October 14, 2025 by and among BioCryst Pharmaceuticals,” at Astria Therapeutics, Inc., 2025-2026
Asset manager	For	Vote
Vanguard	1,951,873	For
Fidelity	870,835	For
Investment Managers Series Trust II	662,738	For
Charles Schwab	343,718	For
Dimensional	121,077	For
Equitable	102,597	For
TIAA	90,426	For
American Century	84,106	For
New York Life	30,770	For
ALPS ETF Trust	26,220	For
ETFis Series Trust I	24,635	For
Lincoln Financial	21,100	For
Northern Trust	20,702	For
Global X	17,869	For
AIG/SunAmerica	17,591	For
Brighthouse	16,425	For
State Street	13,152	For
Pacific Life	13,126	For
Guggenheim	10,727	For
ProShares	10,218	For
Nationwide	6,814	For
DWS	5,548	For
Victory Capital	5,043	For
Virtus	4,966	For
T. Rowe Price	3,873	For

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

4. To adopt the Agreement and Plan of Merger, dated as of October 14, 2025 by and among BioCryst Pharmaceuticals, Inc. (''BioCryst''), Axel Merger Sub, Inc., a wholly owned subsidiary of BioCryst (''Merger Sub''), and Astia Therapeutics, Inc. (''Astia''), under which Merger Sub will merge with and into Astia, with Astia surviving and becoming a wholly owned subsidiary of BioCryst (the ''Merger'') (th

CORPORATE GOVERNANCE

100% fund support · no official result

FOR 100%

The 11 asset managers below cast 100% of the shares they voted on this item FOR (2,540,337 for, 0 against).

FOR: 2,540,337 (100.0%)

Largest asset managers voting on “To adopt the Agreement and Plan of Merger, dated as of October 14, 2025 by and among BioCryst Pharmaceuticals,” at Astria Therapeutics, Inc., 2025-2026
Asset manager	For	Vote
BlackRock	1,702,758	For
ARBITRAGE FUNDS	389,533	For
Morningstar Funds Trust	115,651	For
ALTSHARES TRUST	88,638	For
Tidal Trust II	75,288	For
Bridge Builder Trust	71,393	For
QUANTITATIVE MASTER SERIES LLC	65,938	For
John Hancock	12,172	For
MASTER INVESTMENT PORTFOLIO	10,886	For
Gabelli	8,000	For
WILSHIRE MUTUAL FUNDS INC	80	For

Largest Astria Therapeutics, Inc. shareholders voting in 2025-2026

Ranked by the number of Astria Therapeutics, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting.

Top Astria Therapeutics, Inc. shareholders by shares voted, 2025-2026
#	Asset manager	Shares voted
1	PERCEPTIVE ADVISORS LLC	4,460,827
2	BlackRock	3,219,752
3	GLAZER CAPITAL, LLC	2,955,200
4	Vanguard	2,249,009
5	AllianceBernstein	1,718,108
6	Magnetar Financial LLC	1,570,230
7	GEODE CAPITAL MANAGEMENT, LLC	1,008,484
8	ADAGE CAPITAL PARTNERS GP, L.L.C.	900,000
9	Gabelli	887,000
10	Fidelity	876,739

Shown as share counts, not percentages: no shares-outstanding figure has been matched to Astria Therapeutics, Inc. for the 2025-2026 season, so there is no denominator to divide by.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At Astria Therapeutics, Inc.'s shareholder meeting held 2026-01-21, in the 2025-2026 proxy season, 155 asset managers reported how they voted in their SEC Form N-PX filings, covering 548 separate fund positions. Their filings are grouped here into 4 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To cast a vote, on a non-binding, advisory basis, to approve the Merger-related named executive… — the proposal passed with 94% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Astria Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-01-21.

Astria Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).